Ignite Creation Date:
2025-12-25 @ 1:05 AM
Ignite Modification Date:
2026-03-04 @ 8:46 PM
Study NCT ID:
NCT02815293
Status:
TERMINATED
Last Update Posted:
2019-02-19
First Post:
2016-06-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015352', 'term': 'Dry Eye Syndromes'}], 'ancestors': [{'id': 'D007766', 'term': 'Lacrimal Apparatus Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'clinicaltrials@allergan.com', 'phone': '877-277-8566', 'title': 'Therapeutic Area Head', 'organization': 'Allergan, Inc.'}, 'certainAgreement': {'otherDetails': 'As this study was terminated, no data will be published.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Due to study termination, the study was underpowered'}}, 'adverseEventsModule': {'timeFrame': 'Up to 223 days', 'description': 'Adverse Events reported for randomized patients only', 'eventGroups': [{'id': 'EG000', 'title': 'AGN-195263', 'description': 'One drop of 0.1% AGN-195263 instilled in each eye twice daily', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 0, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Vehicle', 'description': 'One drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.', 'otherNumAtRisk': 8, 'deathsNumAtRisk': 8, 'otherNumAffected': 2, 'seriousNumAtRisk': 8, 'deathsNumAffected': 0, 'seriousNumAffected': 1}], 'otherEvents': [{'term': 'Conjunctival haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}, {'term': 'Eye irritation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 1}], 'organSystem': 'Eye disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}], 'seriousEvents': [{'term': 'Laceration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 10, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 8, 'numAffected': 1}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'AGN-195263', 'description': 'One drop of 0.1% AGN-195263 instilled in each eye twice daily'}, {'id': 'OG001', 'title': 'Vehicle', 'description': 'One drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.66', 'spread': '0.513', 'groupId': 'OG000'}, {'value': '1.75', 'spread': '0.204', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': '6 month visit', 'description': 'The overall ocular discomfort will be assessed on a questionnaire using a 0 to 4 scale on which 0=none, 1=mild, 2=moderate, 3=severe and 4=very severe.', 'unitOfMeasure': 'Score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Efficacy analyses including the overall ocular discomfort score were planned for the intent-to-treat (ITT) population who are defined as all randomized patients. Ultimately, these analyses were not fully performed due to the early termination of the study and only six patients reaching the 6 month visit.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Tearfilm Break Up Time (TBUT)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'AGN-195263', 'description': 'One drop of 0.1% AGN-195263 instilled in each eye twice daily'}, {'id': 'OG001', 'title': 'Vehicle', 'description': 'One drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.18', 'spread': '0.284', 'groupId': 'OG000'}, {'value': '3.16', 'spread': '0.286', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (day 1) to 6 month visit', 'description': 'For TBUT, the mean of 3 measurements of time in seconds will be computed at each visit for each eye. The mean value of the study eye will be used for analysis', 'unitOfMeasure': 'Seconds', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Efficacy analyses including the change from baseline in Tearfilm Break Up Time (TBUT) were planned. Ultimately, these analyses were not fully performed due to the early termination of the study and only six patients reaching the 6 month visit.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'AGN-195263', 'description': 'One drop of 0.1% AGN-195263 instilled in each eye twice daily'}, {'id': 'FG001', 'title': 'Vehicle', 'description': 'One drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.'}, {'id': 'FG002', 'title': 'Enrolled But Not Randomized', 'description': 'Run-In period before randomization'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '8'}, {'groupId': 'FG002', 'numSubjects': '18'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '8'}, {'groupId': 'FG002', 'numSubjects': '18'}]}], 'dropWithdraws': [{'type': 'Study termination by sponsor', 'reasons': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'Participants not randomized', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '18'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}]}]}], 'recruitmentDetails': 'Of the 36 participants who enrolled in the study, 18 were randomized and received intervention to comprise the safety and Intent to Treat (ITT) populations', 'preAssignmentDetails': 'This study was terminated'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}, {'value': '36', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'AGN-195263', 'description': 'One drop of 0.1% AGN-195263 instilled in each eye twice daily'}, {'id': 'BG001', 'title': 'Vehicle', 'description': 'One drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.'}, {'id': 'BG002', 'title': 'Enrolled But Not Randomized', 'description': 'Run-In period before randomization'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}, {'value': '36', 'groupId': 'BG003'}]}], 'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}]}, {'title': '>=65 years', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}, {'value': '18', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}, {'value': '36', 'groupId': 'BG003'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '22', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '14', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '18', 'groupId': 'BG002'}, {'value': '36', 'groupId': 'BG003'}]}], 'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}, {'value': '3', 'groupId': 'BG003'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '6', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}]}, {'title': 'White', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}, {'value': '24', 'groupId': 'BG003'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'BMI', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '30', 'groupId': 'BG003'}]}], 'categories': [{'measurements': [{'value': '27.43', 'spread': '4.4580376849013', 'groupId': 'BG000'}, {'value': '27.3375', 'spread': '4.8256961932969', 'groupId': 'BG001'}, {'value': '29.6', 'spread': '7.4233864689013', 'groupId': 'BG002'}, {'value': '28.1225', 'spread': '1.3197836926109', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'weight (kg) / height (m)^2', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'Data missing for 6 out of the 18 participants in the enrolled but not randomized arm.'}, {'title': 'Weight', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '30', 'groupId': 'BG003'}]}], 'categories': [{'measurements': [{'value': '73.32', 'spread': '11.022504252664', 'groupId': 'BG000'}, {'value': '74.3', 'spread': '16.250384610833', 'groupId': 'BG001'}, {'value': '82.68', 'spread': '19.69071093745', 'groupId': 'BG002'}, {'value': '76.76', 'spread': '3.5637743007958', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'Kg', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'Data missing for 6 out of the 18 participants in the enrolled but not randomized arm.'}, {'title': 'Height', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '8', 'groupId': 'BG001'}, {'value': '12', 'groupId': 'BG002'}, {'value': '30', 'groupId': 'BG003'}]}], 'categories': [{'measurements': [{'value': '163.78', 'spread': '8.5922988774833', 'groupId': 'BG000'}, {'value': '165.0875', 'spread': '17.14697039567', 'groupId': 'BG001'}, {'value': '167.63', 'spread': '9.8016438530597', 'groupId': 'BG002'}, {'value': '165.499', 'spread': '3.7800461794887', 'groupId': 'BG003'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'cm', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'Data missing for 6 out of the 18 participants in the enrolled but not randomized arm.'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2016-10-26', 'size': 792570, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2018-09-07T16:33', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 36}}, 'statusModule': {'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2016-09-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-02', 'completionDateStruct': {'date': '2017-06-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-02-15', 'studyFirstSubmitDate': '2016-06-24', 'resultsFirstSubmitDate': '2018-06-18', 'studyFirstSubmitQcDate': '2016-06-24', 'lastUpdatePostDateStruct': {'date': '2019-02-19', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-02-15', 'studyFirstPostDateStruct': {'date': '2016-06-28', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-02-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-06-21', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Overall Ocular Discomfort Score (0 to 4 Scale; 0=None, 4=Very Severe)', 'timeFrame': '6 month visit', 'description': 'The overall ocular discomfort will be assessed on a questionnaire using a 0 to 4 scale on which 0=none, 1=mild, 2=moderate, 3=severe and 4=very severe.'}], 'secondaryOutcomes': [{'measure': 'Change From Baseline in Tearfilm Break Up Time (TBUT)', 'timeFrame': 'Baseline (day 1) to 6 month visit', 'description': 'For TBUT, the mean of 3 measurements of time in seconds will be computed at each visit for each eye. The mean value of the study eye will be used for analysis'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['EDE', 'evaporative dry eye'], 'conditions': ['Dry Eye Syndromes']}, 'descriptionModule': {'briefSummary': 'The objectives of this study are twofold\n\n* To evaluate the safety and efficacy of 0.1% AGN-195263 administered twice daily compared to its vehicle in patients with evaporative dry eye (EDE)\n* To evaluate the systemic pharmacokinetics of 0.1% AGN-195263 administered twice daily in patients with EDE'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Male, 18 years of age or older, at the screening (day -51) visit OR\n* Females, who are naturally postmenopausal (permanent cessation of menstrual periods for at least 12 consecutive months) or are permanently sterilized (ie, eg, tubal occlusion, hysterectomy, bilateral salpingectomy, and/or bilateral oophorectomy) at the screening (day -51) visit\n* In at least 1 eye, all of the following objective measures of evaporative dry eye (EDE) must be present at the standardization (day -21) and baseline (day 1) visits. The same eye must qualify at both visits\n\n * Tear film break-up time (TBUT) ≥ 2 seconds and ≤ 7 seconds\n * Corneal sodium fluorescein staining score ≥ 1 and ≤ 4 (Oxford scheme)\n * Anesthetized Schirmer's tear test score ≥ 10 mm after 5 minutes\n* At the standardization (day -21) and baseline (day 1) visits, patients must have:\n\n * Ocular Surface Disease Index© (OSDI) score \\> 12 (0 to 100 scale)\n * Overall ocular discomfort score ≥ 1 and \\< 4 (0 to 4 scale; 0 = none, 4 = very severe)\n * Ocular burning score ≥ 1 and \\< 4 (0 to 4 scale; 0 = none, 4 = very severe)\n * Blurred vision score ≥ 1 and \\< 4 (0 to 4 scale; 0 = none, 4 = very severe)\n* In at least 1 eye, a lower lid margin meibum quality global assessment score ≥ 1 at the standardization (day -21) and baseline (day 1) visits. The same eye must qualify at both visits\n* In at least 1 eye, the number of lower lid margin expressible meibomian glands must be ≥ 3 at the standardization (day -21) and baseline (day 1) visits. The same eye must qualify at both visits\n* Use of an artificial tear product or lid hygiene (ie, warm compress, lid massage, lid scrub) for the treatment of dry eye disease, EDE or meibomian gland disease within 1 year of the standardization (day -21) visit\n\nExclusion Criteria:\n\n* Male patients with a history of, known, or suspected prostate cancer\n* Male patients with a prostate-specific antigen (PSA) level ≥ 4 μg/L\n* Female patients with a history of known or suspected breast, cervical, ovarian, or uterine cancer\n* Female patient who is of child-bearing potential\n* At standardization (day -21) and / or baseline (day 1) visits, a lower lid margin meibum quality global assessment score of non-expressible (NE) in either eye\n* Patients who are currently or have used hormone replacement therapy or estrogen and /or progesterone based products (including herbal and nutritional supplements) within 90 days of the standardization (day -21) visit or anticipated use during the study\n* Patients who are currently using or have used any androgen or anti-androgen treatment (including herbal and nutritional supplements), within 90 days of the standardization (day -21) visit or anticipated use during the study\n* Patients who are currently using or have used any hair growth product within 90 days of the standardization (day -21) visit or anticipated use during the study\n* Patients who are currently using or have used corticosteroids administered via any route within 30 days prior to the standardization (day -21) visit, or any anticipated use via any route of administration prior to the month 6 visit\n* Patients who are currently using or have used oral or topical macrolides, tetracycline, tetracycline derivative drugs (including doxycycline and minocycline), retinoids (eg, isotretinoin), or calcineurin inhibitors (ie, RESTASIS®, Ikervis®) within 60 days of the standardization (day -21) visit, or anticipated use prior to the month 6 visit"}, 'identificationModule': {'nctId': 'NCT02815293', 'briefTitle': 'Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye', 'organization': {'class': 'INDUSTRY', 'fullName': 'Allergan'}, 'officialTitle': 'Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye', 'orgStudyIdInfo': {'id': '195263-009'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'AGN-195263', 'interventionNames': ['Drug: AGN-195263']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Vehicle', 'interventionNames': ['Drug: Vehicle']}], 'interventions': [{'name': 'AGN-195263', 'type': 'DRUG', 'description': '1 drop of AGN-195263 will be instilled in each eye twice daily.', 'armGroupLabels': ['AGN-195263']}, {'name': 'Vehicle', 'type': 'DRUG', 'description': '1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.', 'armGroupLabels': ['Vehicle']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85225', 'city': 'Chandler', 'state': 'Arizona', 'country': 'United States', 'facility': 'Arizona Eye Center', 'geoPoint': {'lat': 33.30616, 'lon': -111.84125}}, {'zip': '92835', 'city': 'Fullerton', 'state': 'California', 'country': 'United States', 'facility': 'Clearsight', 'geoPoint': {'lat': 33.87029, 'lon': -117.92534}}, {'zip': '92843', 'city': 'Garden Grove', 'state': 'California', 'country': 'United States', 'facility': 'Orange County Ophthalmology Medical Group', 'geoPoint': {'lat': 33.77391, 'lon': -117.94145}}, {'zip': '90640', 'city': 'Montebello', 'state': 'California', 'country': 'United States', 'facility': 'Montebello Medical Center, Inc.', 'geoPoint': {'lat': 34.00946, 'lon': -118.10535}}, {'zip': '92663', 'city': 'Newport Beach', 'state': 'California', 'country': 'United States', 'facility': 'Eye Research Foundation', 'geoPoint': {'lat': 33.61891, 'lon': -117.92895}}, {'zip': '94954', 'city': 'Petaluma', 'state': 'California', 'country': 'United States', 'facility': 'North Bay Eye Associates', 'geoPoint': {'lat': 38.23242, 'lon': -122.63665}}, {'zip': '95670', 'city': 'Rancho Cordova', 'state': 'California', 'country': 'United States', 'facility': 'Martel Eye Medical Group', 'geoPoint': {'lat': 38.58907, 'lon': -121.30273}}, {'zip': '80016', 'city': 'Centennial', 'state': 'Colorado', 'country': 'United States', 'facility': 'Centennial Eye and Cosmetic Associates', 'geoPoint': {'lat': 39.57916, 'lon': -104.87692}}, {'zip': '80134', 'city': 'Parker', 'state': 'Colorado', 'country': 'United States', 'facility': 'Specialty Eye Care', 'geoPoint': {'lat': 39.5186, 'lon': -104.76136}}, {'zip': '33904', 'city': 'Cape Coral', 'state': 'Florida', 'country': 'United States', 'facility': 'Argus Research at Cape Coral Eye Center', 'geoPoint': {'lat': 26.56285, 'lon': -81.94953}}, {'zip': '34239', 'city': 'Sarasota', 'state': 'Florida', 'country': 'United States', 'facility': 'Sarasota Retina Institute', 'geoPoint': {'lat': 27.33643, 'lon': -82.53065}}, {'zip': '30260', 'city': 'Morrow', 'state': 'Georgia', 'country': 'United States', 'facility': 'Eye Care Centers Management, Inc. dba Clayton Eye Center', 'geoPoint': {'lat': 33.58317, 'lon': -84.33937}}, {'zip': '40217', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Taustine Eye Center', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '20815', 'city': 'Chevy Chase', 'state': 'Maryland', 'country': 'United States', 'facility': 'Eye Doctors of Washington', 'geoPoint': {'lat': 39.00287, 'lon': -77.07115}}, {'zip': '65804', 'city': 'Springfield', 'state': 'Missouri', 'country': 'United States', 'facility': 'Mercy Medical Research Institute', 'geoPoint': {'lat': 37.21533, 'lon': -93.29824}}, {'zip': '63131', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Ophthalmology Consultants, Ltd', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '63090', 'city': 'Washington', 'state': 'Missouri', 'country': 'United States', 'facility': 'Comprehensive Eye Care', 'geoPoint': {'lat': 38.55811, 'lon': -91.01209}}, {'zip': '27262', 'city': 'High Point', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Cornerstone Eye Care, LLC', 'geoPoint': {'lat': 35.95569, 'lon': -80.00532}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'University Hospitals of Cleveland', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '29464', 'city': 'Mt. Pleasant', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Carolina Macula and Retina', 'geoPoint': {'lat': 32.79407, 'lon': -79.86259}}, {'zip': '37205', 'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Nashville Vision Associates, LLC', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Robert Cizik Eye Clinic', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77339', 'city': 'Kingwood', 'state': 'Texas', 'country': 'United States', 'facility': 'Houston Eye Associates', 'geoPoint': {'lat': 30.05691, 'lon': -95.18349}}, {'zip': '77566', 'city': 'Lake Jackson', 'state': 'Texas', 'country': 'United States', 'facility': 'Brazosport Eye Institute', 'geoPoint': {'lat': 29.03386, 'lon': -95.43439}}, {'zip': '77573', 'city': 'League City', 'state': 'Texas', 'country': 'United States', 'facility': 'The Eye Clinic of Texas, an affiliate of Houston Eye Associates', 'geoPoint': {'lat': 29.50745, 'lon': -95.09493}}, {'zip': '78572', 'city': 'Mission', 'state': 'Texas', 'country': 'United States', 'facility': 'DCT- Shah Research, LLC dba Discovery Clinical Trials', 'geoPoint': {'lat': 26.21591, 'lon': -98.32529}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'R and R Eye Research, LLC', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '84117', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'Stacy R. Smith, M.D., P.C.', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '53405', 'city': 'Racine', 'state': 'Wisconsin', 'country': 'United States', 'facility': 'The Eye Centers of Racine and Kenosha', 'geoPoint': {'lat': 42.72613, 'lon': -87.78285}}], 'overallOfficials': [{'name': 'Medical Director', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Allergan'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Allergan', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}